Abstract: The present invention relates to methods for assessing one's risk for suffering from severe COVID or long COVID symptoms. Also provided are methods for reducing the risk of developing severe COVID and/or long COVID symptoms.

Abstract: An ultrasonic transducer that is configured to selectively operate at first or second resonant frequency during wire bonding operations includes an elongated transducer body an aperture for mounting a piezoelectric driver stack for driving the ultrasonic transducer to operate at the first or second resonant frequency and a mounting flange connected to the transducer body at a first nodal vibration region of the transducer body when the ultrasonic transducer is operated at the first resonant frequency. The elongated transducer has a length substantially equal to two wavelengths of a first oscillatory wave that is transmitted along the length of the transducer body when the transducer is operated at the first resonant frequency, and substantially equal to a half wavelength of a second oscillatory wave that is transmitted along the length of the transducer body when the transducer is operated at the second resonant frequency.

Abstract: An ultrasonic transducer includes an elongated transducer body with an aperture for mounting a piezoelectric driver stack for driving the ultrasonic transducer to operate at a first resonant frequency, a mounting flange for mounting the transducer body to a wire bonding machine, a rigid connecting member having first and second ends which are respectively connected to the mounting flange and the transducer body at a first nodal vibration region of the transducer body when the ultrasonic transducer is operated at the first resonant frequency and a flexible connecting member extending between the mounting flange and the transducer body at a second nodal vibration region of the transducer body when the ultrasonic transducer is operated at the first resonant frequency.

Abstract: The present disclosure provides EBNA1 and LMP1 dual-targeting peptides and upconversion nanoparticles conjugates comprising the same useful as therapeutic and theranostic agents capable of targeting EBNA1 and LMP1 proteins present in Epstein-Barr virus infected cells, such as cancer.

Abstract: The present invention resides in the discovery that altered abundance of fungal species in the gut and feces of both fecal microbiota transplantation (FMT) donors and recipients may influence the outcome of FMT treatment. Thus, novel methods are provided for identifying subjects as suitable donor or recipients for FMT, for assessing the likelihood of FMT treatment success, and for enhancing FMT treatment efficacy. Also provided are kits and compositions for FMT with enhanced efficacy.

Abstract: A detection system (100) and a method for identifying structural change (300) with a substrate (200) includes a sensor (101) configured to resonate at variable frequencies, the resonant frequency of the sensor changing in response to structural change in the substrate, a detector (102) located in proximity to the sensor for detecting the resonant frequency of the sensor, and a receiving device (103) in communication with the detector for receiving information output by the detector, an analyzing device (108) in communication with the receiving device for and interpreting information output by the receiving device. The sensor includes an engagement surface for engaging the substrate. The detector is located on the sensor and away from the engagement surface in such a way that the sensor and the detector are arranged to form a laminated structure.

Abstract: Methods are provided for treating metabolic diseases by way of modulating recipients' gastrointestinal tract microorganism profile such as by fecal microbiota transplantation (FMT) treatment. Also provided are methods for assessing a patient's risk of developing obesity and/or related metabolic diseases. Further provided are kits and compositions for use in these methods.

Abstract: Provided are methods for treating symptoms of autism spectrum disorder (ASD) in a human child. Methods for determining risk for A SD in human children, methods for assessing developmental age of children and for treating children in need thereof, kits and compositions for use in these methods are also provided.

Abstract: Methods and compositions for treating and/or preventing a bacterial infection in a subject are provided, in which the subject is administered a fecal sample obtained from a donor subject via fecal microbiota transplantation (FMT). The fecal sample contains bacteriophages that target the bacteria causing the infection. In some embodiments, the fecal sample containing the bacteriophages can be obtained from a donor subject who previously had the same infection but is now cured.

Abstract: Methods are provided for treating COVID-19 patients to facilitate their recovery from the disease as well as for prognosis of severity of COVID-19 among patients who have been infected by SARS-CoV-2. Also provided are kits and compositions for use in these methods.

Abstract: A probiotic composition comprising Bifidobacterium bifidum and Bifidobacterium longum, and may further comprising Bifidobacterium adolescentis and Lactobacillus rhamnosus is provided. A prebiotic composition comprising xylooligosaccharide, galactooligosaccharide, and corn dietary fiber, and a dietary composition comprising the probiotic composition and the prebiotic composition are provided. Use of the foregoing compositions in the preparation of a dietary product or a drug for assisting in preventing and/or treating a pathogen infection of an individual, enhancing the therapeutic effect of a pathogen infection of an individual, improving the immunity of an individual, or balancing the gut microecology of an individual is provided. The foregoing compositions can be used in patients suffering from COVID-19.

Abstract: The present invention provides for compositions and methods for treating long COVID symptoms or reducing the risk of developing such symptoms.

Abstract: Certain microorganism species in a composition for use in fecal microbiota transplantation (FMT), including fecal material obtained from an FMT donor, can affect the outcome of FMT treatment such as regulating the bodyweight and cholesterol level in FMT recipients. Thus, methods are provided for identifying subjects as suitable donor to optimize FMT outcome and for pretreating donors and/or recipients for optimized FMT outcome. Also provided are kits and compositions for improving FMT outcome, including for bodyweight and/or cholesterol reduction.

Abstract: Polypeptides useful for treating and/or imaging latent membrane protein 1 positive cells, such as cells infected with Epstein-Barr virus and Epstein-Barr virus-associated cancers, pharmaceutical compositions comprising the same, and methods of use thereof.

Abstract: The present disclosure provides EBNA1 and LMP1 dual-targeting peptides and upconversion nanoparticles conjugates comprising the same useful as therapeutic and theranostic agents capable of targeting EBNA1 and LMP1 proteins present in Epstein-Barr virus infected cells, such as cancer.

Abstract: Provided herein are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.

Abstract: The disclosed systems and methods are directed to generating cache IDs for each of a plurality of AI training pipelines, accessing training data elements included in a training data set, generating IDs corresponding to the training data elements, receiving the data IDs and an associated cache ID, randomizing the data IDs, selecting a subset of the randomized data IDs, fetching the training data elements previously cached by a cache node, receiving a portion of the training data elements present in the caching server corresponding to the subset of randomized data IDs, forwarding the portion of the training data elements present in the caching server to at least one consumer node, fetching the remaining training data elements associated with the subset of randomized data IDs from the training data set, and forwarding the remaining training data elements to at least one transformation node for training the neural network.

Abstract: Disclosed is a computer implemented method for time stamping and transferring intellectual property right, including the following steps: enrolling plurality of corresponding nodes to a platform; wherein the corresponding nodes include administration node, a public node, super node, child node, independent individual professor node and a service node; uploading information and document of the intellectual property right to the platform by independent individual professor node, super node or child node; wherein the information and document upon uploaded to the platform is time stamped; searching relevant intellectual property right on the platform; negotiating on the platform; composing a customized digital agreement on the platform by selecting, amending and/or adding on a relevant module clause; wherein the customized digital agreement has smart contract functions for automating execution; signing the agreement digitally by corresponding parties; blocking the intellectual property right automatically for fur

Abstract: The invention provides luminescent lanthanide nanoparticles having simultaneously an improved brightness and an increased lifetime of the excited-state. These nanoparticles comprise terbium ions and ions of a second lanthanide, preferentially europium, and are coated with molecules of chromophore ligand bonded to the surface of the nanoparticle. The ligand is an organic molecule comprising at least one chromophore radical of formula (I) or of formula (II): wherein R is selected from H, CN group or COOH group. The phosphorescence excited-state lifetime is improved by energy transfer from surface terbium ions to core ions of the second lanthanide The nanoparticle may further comprise a carrier molecule of analytical interest covalently attached to at least one ligand molecule.

Abstract: The present disclosure relates to compounds useful in the treatment, imaging, and/or diagnosis of Epstein-Barr virus (EBV)-positive cells, such as cancer.